Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Malignant Neoplasm in the Bone|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab|DRUG: Ruxolitinib Phosphate
Sponsor: Mayo Clinic